HC Wainwright Has Bearish Estimate for VNDA Q3 Earnings

Key Points

• HC Wainwright has revised its Q3 2025 earnings estimate for Vanda Pharmaceuticals, predicting a loss of $0.31 per share, down from its previous estimate of $0.28.
• Vanda's recent earnings report revealed a loss of $0.46 per share for the last quarter, missing analysts' expectations by $0.12.
• Insider trading activity included CEO Mihael Hristos Polymeropoulos purchasing 10,000 shares at $4.40 each, reflecting a growing confidence in the company's future despite its current challenges.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) - Equities research analysts at HC Wainwright decreased their Q3 2025 earnings per share estimates for Vanda Pharmaceuticals in a research report issued to clients and investors on Tuesday, August 12th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will post earnings of ($0.31) per share for the quarter, down from their prior estimate of ($0.28). HC Wainwright currently has a "Buy" rating and a $20.00 price target on the stock. The consensus estimate for Vanda Pharmaceuticals' current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for Vanda Pharmaceuticals' Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($1.47) EPS, Q2 2026 earnings at $0.02 EPS and FY2026 earnings at $0.05 EPS.

Other analysts have also issued research reports about the company. Wall Street Zen lowered Vanda Pharmaceuticals from a "hold" rating to a "strong sell" rating in a report on Saturday, August 2nd. Cantor Fitzgerald restated an "overweight" rating and set a $13.00 target price on shares of Vanda Pharmaceuticals in a report on Wednesday, May 14th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Strong Buy" and a consensus target price of $16.50.

Vanda Pharmaceuticals Stock Performance

Vanda Pharmaceuticals stock traded down $0.0350 during mid-day trading on Thursday, reaching $4.5250. 127,033 shares of the company were exchanged, compared to its average volume of 570,899. The business has a fifty day moving average of $4.61 and a 200 day moving average of $4.53. The firm has a market cap of $267.38 million, a P/E ratio of -4.00 and a beta of 0.72. Vanda Pharmaceuticals has a 12-month low of $3.81 and a 12-month high of $5.55.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.12). The firm had revenue of $52.59 million during the quarter, compared to analysts' expectations of $54.77 million. Vanda Pharmaceuticals had a negative net margin of 32.90% and a negative return on equity of 12.89%. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS.

Insider Transactions at Vanda Pharmaceuticals

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 7,000 shares of Vanda Pharmaceuticals stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $4.59, for a total transaction of $32,130.00. Following the completion of the sale, the director owned 97,082 shares of the company's stock, valued at approximately $445,606.38. The trade was a 6.73% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of the stock in a transaction on Wednesday, May 21st. The shares were purchased at an average cost of $4.40 per share, with a total value of $44,000.00. Following the transaction, the chief executive officer owned 2,325,731 shares in the company, valued at $10,233,216.40. This trade represents a 0.43% increase in their position. The disclosure for this purchase can be found here. Insiders own 8.90% of the company's stock.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VNDA. JPMorgan Chase & Co. grew its position in Vanda Pharmaceuticals by 108.9% during the 4th quarter. JPMorgan Chase & Co. now owns 335,741 shares of the biopharmaceutical company's stock worth $1,608,000 after purchasing an additional 175,019 shares during the period. Geode Capital Management LLC grew its position in Vanda Pharmaceuticals by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 1,450,310 shares of the biopharmaceutical company's stock worth $6,949,000 after purchasing an additional 24,483 shares during the period. Wells Fargo & Company MN grew its position in Vanda Pharmaceuticals by 28.0% during the 4th quarter. Wells Fargo & Company MN now owns 33,509 shares of the biopharmaceutical company's stock worth $161,000 after purchasing an additional 7,339 shares during the period. Barclays PLC grew its position in Vanda Pharmaceuticals by 15.6% during the 4th quarter. Barclays PLC now owns 178,368 shares of the biopharmaceutical company's stock worth $854,000 after purchasing an additional 24,071 shares during the period. Finally, XTX Topco Ltd acquired a new stake in Vanda Pharmaceuticals during the 4th quarter worth about $69,000. 88.14% of the stock is owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.